Brooks Laboratories share price & results
- Jun 2026
- Jun 2026
Himachal Pradesh-based pharma manufacturer of formulations, serving CDMO/third-party, institutional and Critical Care Division customers, with exports to semi-regulated markets across Africa, LATAM and Asia.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 23.0 | −10.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 8.1 | −4.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.4 | −46.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 12.01 | +35.0 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 6.71 | +4.2 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | -7.71 | −1.4 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −47.3% 1Y
1Y: ₹113.3 on 24 Oct 2025 → ₹59.72. High ₹113.3 (24 Oct 2025), low ₹37.11 (30 Mar 2026).
- Previous close
- ₹57.86
- Market cap
- ₹159 Cr
- 52-week range
- ₹37.11 – ₹112.1
- One year
- −46.73%
- Price to earnings (TTM to Jun 2026)
- 12.04×
- Return on equity (TTM to Jun 2026)
- 12.01%
Overview
- Symbol
- NSE:BROOKS
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Brooks Laboratories Limited does
Based on the company's own presentations, annual report and earnings calls.
Brooks Laboratories manufactures and markets pharmaceutical formulations from its unit at Baddi, Himachal Pradesh, acting as a CDMO/third-party manufacturer for other pharma companies while also supplying institutional and hospital buyers directly. Its Critical Care Division (CCD), established in 2018, sells critical-care, antibiotic, pain-management/nutritional and ophthalmic products to hospitals through a pan-India team of about 140 medical sales professionals. The company also exports formulations to semi-regulated and non-regulated markets in Africa, Latin America and Asia under manufacturing-facility accreditations from regulators in Yemen, Afghanistan, Cambodia, Ivory Coast and Nigeria, holding over 50 market authorisations across a portfolio of 95+ products.
Segments
- India – CDMO, Third-Party & Institutional Business
- Critical Care Division (CCD)
- International / Export Business
- Manufacturing facility
- 1 unit at Baddi, Himachal Pradesh
- Product portfolio
- 95+ products
- Market authorisations
- 50+
- Facility regulatory accreditations
- Accredited by regulators in Yemen, Afghanistan, Cambodia, Ivory Coast & Nigeria
- Export markets
- 13+ countries incl. Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan, Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, plus other LATAM & Africa regions
- Critical Care Division sales team
- ~140 medical sales professionals, pan-India
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −46% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 21 | 23 | 26 | 23 | 17 | 20 | 23 |
| Expenses | 19 | 19 | 22 | 22 | 21 | 16 | 20 | 21 |
| Operating profit | 2 | 2 | 2 | 3 | 3 | 1 | 1 | 2 |
| Operating margin | 7.3% | 7.7% | 6.8% | 12.2% | 10.8% | 4.4% | 3.4% | 8.1% |
| Other income | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 1 | 2 | 3 | 2 | 0 | 1 | 1 |
| Tax rate | 0.0% | 0.0% | 11.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | 1 | 1 | 1 | 3 | 2 | 0 | 1 | 1 |
| EPS (₹ per share) | 0.37 | 0.36 | 0.47 | 0.90 | 0.76 | 0.10 | 0.21 | 0.48 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 63 | 79 | 83 | 86 |
| Expenses | 90 | 76 | 78 | 79 |
| Operating profit | -26 | 3 | 5 | 7 |
| Other income | 1 | 1 | 1 | 1 |
| Interest | 2 | 1 | 1 | 1 |
| Depreciation | 7 | 2 | 2 | 2 |
| Profit before tax | -35 | 2 | 3 | 6 |
| Net profit | -27 | 2 | 3 | 6 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 25 | 25 | 26 | 29 | 29 | 29 |
| Reserves | 40 | 32 | 43 | 86 | 86 | 91 |
| Borrowings | 6 | 7 | 6 | 8 | 8 | 9 |
| Other liabilities | 32 | 29 | 19 | 18 | 16 | 17 |
| Total liabilities | 103 | 92 | 94 | 141 | 140 | 146 |
| Fixed assets | 15 | 15 | 14 | 14 | 13 | 15 |
| Capital work in progress | 1 | 0 | 0 | 0 | 1 | 1 |
| Investments | 47 | 47 | 47 | 91 | 86 | 91 |
| Other assets | 40 | 31 | 34 | 36 | 40 | 40 |
| Total assets | 103 | 92 | 94 | 141 | 140 | 146 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | -1 | 3 | 1 | -10 | 3 | 9 |
| Cash from investing | -1 | 1 | -0 | 0 | -45 | -3 |
| Cash from financing | 1 | -4 | -0 | 10 | 42 | 0 |
| Net cash flow | -0 | 0 | -0 | 0 | -0 | 7 |
| Free cash flow | -2 | 4 | 0 | -10 | 2 | 6 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 46 | 71 | 84 | 75 | 88 | 69 |
| Inventory days | 92 | 120 | 99 | 60 | 61 | 77 |
| Days payable | 99 | 186 | 206 | 97 | 90 | 80 |
| Cash conversion cycle | 38 | 5 | -22 | 38 | 59 | 66 |
| Working capital days | -6 | 2 | -43 | 34 | 43 | 34 |
| Return on capital employed | −5.2% | 1.5% | −11.1% | 3.5% | 4.3% | 5.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Where revenue comes from
The businesses behind the company’s reported revenue.
b) Manufacturing contributes 99.2% of reported segment revenue.
Quarter ended 30 Jun 2026 · Consolidated
- b) Manufacturing 99.2%
₹22.78 crore
- a) Trading 0.8%
₹0.19 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| b) Manufacturing | 22.78 | 99.2% |
| a) Trading | 0.19 | 0.8% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
How these numbers add up
- Total segment revenue
- ₹22.96 crore
- Intersegment adjustment
- ₹0.00 crore
- Net segment revenue
- ₹22.96 crore
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
How the mix has moved
Each segment’s share of reported revenue, quarter by quarter.
| Segment | Sep 2025 | Dec 2025 | Jun 2026 | YoY growth latest quarter |
|---|---|---|---|---|
| b) Manufacturing | — | — | 99% | — |
| a) Trading | — | — | 1% | — |
Share of reported segment revenue by quarter, consolidated basis, as filed. A quarter the company did not report is left blank, never carried forward.
See how segments are shifting across companies → Segment Shift
Ownership
Who owns it
Promoters hold 52.62% as of Jun 2026; institutions cut 0.17 pts since Mar 2026.
- Promoters 52.62%
- Foreign institutions 0.00%
- Domestic institutions 10.38%
- Public 37.00%
Who is on the register
Named in the Jun 2026 filing
Every holder of Brooks Laboratories Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 19.24% | unchanged | |
| 17.36% | unchanged | |
| Mutual fund | 9.90% | unchanged |
| 4.10% | unchanged | |
| 2.92% | unchanged | |
| 2.67% | unchanged | |
| 2.47% | unchanged | |
| 2.34% | unchanged | |
| 1.52% | unchanged | |
| 1.20% | unchanged | |
| 1.02% | −0.13 pp | |
| — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Brooks Laboratories Limited
Free account: one company. Everything above stays public.
Write why you follow Brooks Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Brooks Laboratories Limited
Guides on how to read this kind of business and the numbers that matter.